insure: pooled analysis of patients with r/r multiple myeloma treated with ird in the real-world
Published 2 years ago • 39 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
4:26
outcomes of ird in r/r multiple myeloma in routine clinical practice
-
5:27
uvea-ixa: exploring the use of ixazomib-based therapy in r/r myeloma outside of clinical trials
-
1:47
oral symptom assessment using pros in patients with r/r myeloma treated with talquetamab
-
4:12
insight-mm: real-world analysis of dot with rd-based regimens in r/r myeloma
-
2:45
an analysis of survival outcomes in patients with triple-class refractory myeloma
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
31:04
thriving with myeloma: what you should know about care and treatment
-
2:16
living with multiple myeloma
-
0:52
imroz trial updates: isa-vrd versus vrd in patients with ndmm ineligible for transplant
-
1:59
the role of proteasome inhibitors in the treatment of r/r multiple myeloma
-
0:55
the safety and efficacy of elranatamab in patients with r/r al amyloidosis
-
3:58
the possibility of using mrd as a surrogate endpoint for pfs and os in myeloma clinical trials
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
3:46
a phase ib/ii trial of sonrotoclax plus dexamethasone in patients with r/r mm harboring t(11;14)
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
1:09
the efficacy & role of iberdomide in r/r multiple myeloma
-
0:38
pain management for patients with scd and thalassemia in lebanon
-
1:21
what is the pcrowd study, and how does knowledge in myeloma biology help with new treatments?
-
1:40
utilizing ai for individualized treatment-adjusted risk stratification in newly diagnosed myeloma
-
2:07
key findings of the pooled analysis of the tourmaline-mm3 and mm4 trials
-
4:02
the diagnostic and prognostic value of mass spectrometry in multiple myeloma